16.42
-0.52 (-3.07%)
| Penutupan Terdahulu | 16.94 |
| Buka | 16.36 |
| Jumlah Dagangan | 825,454 |
| Purata Dagangan (3B) | 190,251 |
| Modal Pasaran | 558,545,984 |
| Harga / Buku (P/B) | 2.38 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 May 2025 - 12 May 2025 |
| EPS Cair (TTM) | -2.56 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.07% |
| Nisbah Semasa (MRQ) | 13.14 |
| Aliran Tunai Operasi (OCF TTM) | -70.21 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -48.64 M |
| Pulangan Atas Aset (ROA TTM) | -26.91% |
| Pulangan Atas Ekuiti (ROE TTM) | -39.36% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | ArriVent BioPharma, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 1.5 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -2.5 |
| Purata | 0.38 |
|
ArriVent BioPharma Inc is a clinical stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize team’s deep drug development experience to maximize the potential of lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 9.72% |
| % Dimiliki oleh Institusi | 84.55% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 45.00 (Guggenheim, 174.06%) | Beli |
| Median | 39.00 (137.52%) | |
| Rendah | 37.00 (B. Riley Securities, 125.34%) | Beli |
| Purata | 40.33 (145.62%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 21.05 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| B. Riley Securities | 20 Mar 2025 | 37.00 (125.33%) | Beli | 19.54 |
| Guggenheim | 10 Mar 2025 | 45.00 (174.06%) | Beli | 21.73 |
| HC Wainwright & Co. | 07 Mar 2025 | 39.00 (137.52%) | Beli | 21.87 |
| 22 Jan 2025 | 39.00 (137.52%) | Beli | 26.63 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 03 Mar 2025 | Pengumuman | ArriVent BioPharma Reports Full Year 2024 Financial Results |
| 21 Jan 2025 | Pengumuman | ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |